Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 18.08.2025 1 Am J Ind Med 3 Ann Surg Oncol 3 Ann Thorac Surg 5 BMC Cancer 2 Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Chest 1 Clin Cancer Res 1 Clin Lung Cancer 2 Eur J Cancer 1 J Cancer Res Clin Oncol 2 J Clin Oncol 2 JAMA Oncol 2 Lancet 17 Lung Cancer 1 Nat Genet 1 Oncogene 1 Oncol Rep 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Ind Med

1. CAREY RN, Reid A, de Klerk N, Cinquini P, et al
   Mortality and Cancer Incidence After Exposure to Blue Asbestos in Childhood: A Further 10 Years of Follow-Up.
   Am J Ind Med. 2025;68:772-783.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. XING Y, Zhou J, Yang Z, Dai Z, et al
   Visible Pleural Retraction is a Prognostic Marker in Early-Stage Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
   Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-17946.
   PubMed         Abstract available
   
   
3. UEDA D, Mimae T, Okada M
   Reply to: "Should Muscle Mass be Incorporated into Surgical Decision Making for Early-Stage Lung Cancer?", by Yan et al.
   Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18049.
   PubMed        
   
   
4. HUANG K, Li P, Wu Q, Tang X, et al
   Sleeve Lobectomy, Pulmonary Artery Plasty, and Superior Vena Cava Reconstruction for Locally Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective Study.
   Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-17652.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. GRIFFITH A, Pratt CG, Whitrock JN, Moore AN, et al
   Achieving Equitable Care for Racial Minority Patients with a Lung Cancer Screening Program.
   Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00749.
   PubMed         Abstract available
   
   
6. EZENWANKWO E
   Securing CT Lung Cancer Screening Access: Implications of the Supreme Court's Ruling in Kennedy v. Braidwood.
   Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00755.
   PubMed        
   
   
7. ABDALLAT M, Leo RT, Sugarbaker EA, McAllister M, et al
   Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less Still More?
   Ann Thorac Surg. 2025 Aug 8:S0003-4975(25)00725.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. JIANG Z, Zhao F, Li B, He J, et al
   Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles.
   BMC Cancer. 2025;25:1292.
   PubMed         Abstract available
   
   
9. LOBINGER D, Taylor N, Messner V, Seier S, et al
   Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer.
   BMC Cancer. 2025;25:1297.
   PubMed         Abstract available
   
   
10. LUAN X, Han X, Wang Z, Zhao L, et al
    Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic patterns.
    BMC Cancer. 2025;25:1287.
    PubMed         Abstract available
    
    
11. LIN X, Liu S, Ding Y, Zhao J, et al
    Contrasting tracheal, bronchus, and lung cancer burdens and care quality: a comparative analysis of China and global trends.
    BMC Cancer. 2025;25:1298.
    PubMed         Abstract available
    
    
12. JAPUNTICH SJ, Sacasa NG, Cameron S, Balletto B, et al
    Lung cancer screening experiences among patients with a smoking history and primary care providers: a qualitative study.
    BMC Cancer. 2025;25:1305.
    PubMed         Abstract available
    
    

    
    Cancer

13. STUDTS JL, Carter-Bawa L, Hamann HA, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to facilitate transformation.
    Cancer. 2025;131:e35969.
    PubMed         Abstract available
    
    
14. OLSON JMG, Knight JR, Copeland AM, Ohlander KA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Addressing planning for lung cancer interventions at the state and local level through the creation of the National Lung Cancer Roundtable Planning Tool.
    Cancer. 2025;131:e35954.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

15. PESTARINO L, Fortner RT, Nost TH, Fotopoulos I, et al
    Recommendations for validating omics prediction models: Insights from a lung cancer RNA biomarker study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Chest

16. MURGU S, Chen AC, Gilbert CR, Sterman DH, et al
    A Prospective, Multicenter Evaluation of Safety and Diagnostic Outcomes With Robotic-Assisted Bronchoscopy: Results of the Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung (TARGET) Trial.
    Chest. 2025;168:539-555.
    PubMed         Abstract available
    
    
17. YE Y, An P
    Reassessing Communication Strategies in Lung Cancer Screening: Implications for Patient-Centered Outcomes.
    Chest. 2025;168:e55-e56.
    PubMed        
    
    

    
    Clin Cancer Res

18. CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
    Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

19. TELLI TA, Tatli AM, Alan O, Keskin GY, et al
    Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
    Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00159.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

20. YAMAGUCHI K, Takao S, Kanaji N, Hirakawa T, et al
    The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
    Eur J Cancer. 2025;226:115606.
    PubMed         Abstract available
    
    
21. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. WU X, Fang K, Huang W, Chen G, et al
    Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.
    J Cancer Res Clin Oncol. 2025;151:230.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    PubMed         Abstract available
    
    
24. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    PubMed        
    
    

    
    JAMA Oncol

25. ROLLE LD, Crane TE
    Methodological Concerns With Lung Cancer Screening Estimates-Reply.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
    PubMed        
    
    
26. BURUS T, McAfee CR, Hull PC
    Methodological Concerns With Lung Cancer Screening Estimates.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
    PubMed        
    
    

    
    Lancet

27. SMIT EF, Dingemans AC
    Adagrasib for KRAS(G12C) mutated advanced non-small-cell lung cancer.
    Lancet. 2025;406:576-577.
    PubMed        
    
    
28. BARLESI F, Yao W, Duruisseaux M, Doucet L, et al
    Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
    Lancet. 2025;406:615-626.
    PubMed         Abstract available
    
    

    
    Lung Cancer

29. CUMMINGS AL, Sussell J, Rosettie KL, Moustaid FE, et al
    A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.
    Lung Cancer. 2025;207:108701.
    PubMed         Abstract available
    
    
30. YU Y, Pan Y, Zhou J, Mu S, et al
    Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.
    Lung Cancer. 2025;207:108710.
    PubMed         Abstract available
    
    
31. ALI AS, Irfan M
    Second-hand smoke and survival in former smokers with lung cancer: time to act.
    Lung Cancer. 2025 Aug 11:108713. doi: 10.1016/j.lungcan.2025.108713.
    PubMed        
    
    
32. CHATURVEDI A, Som A
    Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in lung adenocarcinoma.
    Lung Cancer. 2025;206:108540.
    PubMed         Abstract available
    
    
33. HUBERT J, Moldovanu D, van den Bosch I, de Nijs K, et al
    Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial.
    Lung Cancer. 2025;207:108686.
    PubMed         Abstract available
    
    
34. LEE J, Kim M, Han HJ, Kim S, et al
    Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study.
    Lung Cancer. 2025;206:108682.
    PubMed         Abstract available
    
    
35. PRONSATI N, Liu G, Bauer TM, Felip E, et al
    Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
    Lung Cancer. 2025;206:108662.
    PubMed         Abstract available
    
    
36. FUJINO K, Suda K, Yoshikawa M, Shien K, et al
    Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
    Lung Cancer. 2025;206:108672.
    PubMed         Abstract available
    
    
37. LU F, Lv C, Yang X, Zhuo M, et al
    Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
    Lung Cancer. 2025;206:108676.
    PubMed         Abstract available
    
    
38. NIEDERMAIER B, Rolf E, Allgauer M, Klotz LV, et al
    Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma.
    Lung Cancer. 2025;206:108674.
    PubMed         Abstract available
    
    
39. LYNCH GA, Symonds J, Morley A, Azubuike-Dyer E, et al
    Serum mesothelin as a response biomarker in pleural mesothelioma.
    Lung Cancer. 2025;206:108670.
    PubMed         Abstract available
    
    
40. PANDEY A, Gomez E, Soto A, Jr MA, et al
    A novel murine carcinogen-induced model recapitulates the progression and heterogeneity of human lung adenocarcinoma.
    Lung Cancer. 2025;206:108581.
    PubMed         Abstract available
    
    
41. DUMANE V, Runnels J, Flores R, Wolf A, et al
    Long term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma.
    Lung Cancer. 2025;206:108639.
    PubMed         Abstract available
    
    
42. GAGNE A, Alessi JVM, Ricciuti B, Lamberti G, et al
    Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas.
    Lung Cancer. 2025;206:108644.
    PubMed         Abstract available
    
    
43. MEDUSA PM, Carro N, Morgillo F, Guida GD, et al
    Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.
    Lung Cancer. 2025;206:108617.
    PubMed         Abstract available
    
    
44. ZOLOV S, Chuikov S, Katkam SK, Chockley PJ, et al
    Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in lung adenocarcinoma.
    Lung Cancer. 2025;206:108643.
    PubMed         Abstract available
    
    
45. LANGER S, Medenwald D, Vordermark D, Schuette W, et al
    Therapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic review.
    Lung Cancer. 2025;206:108640.
    PubMed         Abstract available
    
    

    
    Nat Genet

46. KLOTZER KA, Abedini A, Li S, Balzer MS, et al
    Analysis of individual patient pathway coordination in a cross-species single-cell kidney atlas.
    Nat Genet. 2025;57:1922-1934.
    PubMed         Abstract available
    
    

    
    Oncogene

47. LIU L, Chen S, Lei Y, Lin Z, et al
    REPS2 attenuates cancer stemness through inhibiting Wnt signaling by autophagy mediated degradation of beta-catenin.
    Oncogene. 2025;44:2942-2955.
    PubMed         Abstract available
    
    

    
    Oncol Rep

48. LEI Y, Guo W, Chen B, Chen L, et al
    [Retracted] Tumor?released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non?small cell lung cancer.
    Oncol Rep. 2025;54:140.
    PubMed         Abstract available
    
    

    
    PLoS One

49. ABDOLLAHI A, Favata M, Weber M, Roman V, et al
    The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
    PLoS One. 2025;20:e0327588.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.